Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Krka DDFRA:KN8 +1.71%71 3-Year ROIIC % is 27.84 as of Dec. 2025, which is 3% below its 10-year median of 28.78. GuruFocus rates FRA:KN8 with a GF Score™ of 71/100 and a GF Value™ of €188.78 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 946 Drug Manufacturers companies, Krka DD ranks better than 76% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Krka DD's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 27.84%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Krka DD's 3-Year ROIIC % or its related term are showing as below:
FRA:KN8's 3-Year ROIIC % is ranked better than 76% of 946
companies
in the Drug Manufacturers industry
Industry Median: 3.72
vs FRA:KN8: 27.84
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Krka DD 3-Year ROIIC % Related Terms
Krka DD 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Krka DD's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:KN8 vs ZTS, UTHR, VTRS: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Krka DD's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krka DD 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Krka DD's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Krka DD's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Krka DD (FRA:KN8) has a 3-Year ROIIC % of 27.84 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Krka DD and its competitors. This is near median its historical median of 28.78. According to the industry distribution chart, Krka DD ranks #227 out of 946 companies in the Drug Manufacturers industry, placing it in the top 24%.
Is Krka DD's 3-Year ROIIC % too high?
Krka DD's current 3-Year ROIIC % of 27.84 is near median its 10-year median of 28.78. The Drug Manufacturers industry median 3-Year ROIIC % is 3.72. Krka DD's value of 27.84 is 648.4% above this industry median. Based on the distribution chart, Krka DD ranks #227 out of 946 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Krka DD has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Krka DD ranks #227 out of 946 companies for 3-Year ROIIC %. This places Krka DD in the top 24% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.72. Krka DD's value of 27.84 is 648.4% above this benchmark. While the company's 10-year median is 28.78 vs. the industry median of 3.72, Krka DD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.72, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krka DD's current 3-Year ROIIC % of 27.84 is 648.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Krka DD and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krka DD's current 3-Year ROIIC % is 27.84, which is near median its own 10-year median of 28.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (FRA:KN8) is currently considered Significantly Overvalued. The stock's GF Value™ is €188.78, compared to a current price of €267.50 — trading 41.7% above its estimated fair value. The current 3-Year ROIIC % is 27.84, which is near median its 10-year median of 28.78 and 648.4% above the Drug Manufacturers industry median of 3.72. Krka DD's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Krka DD (FRA:KN8), the current 3-Year ROIIC % is 27.84 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krka DD (FRA:KN8) Overvalued in 2026?
Based on GuruFocus' analysis, Krka DD stock appears to be overvalued.
The current stock price of €267.50 is trading 41.7% above its estimated GF Value™ of €188.78.
GuruFocus considers Krka DD to be Significantly Overvalued.
Key valuation signals for FRA:KN8:
3-Year ROIIC %: 27.84 (near median its 10-year median of 28.78)
GF Value™: €188.78 vs. price of €267.50 (41.7% above fair value)
Industry Position: 648.4% above the Drug Manufacturers median (#227 of 946)
No single metric tells the full story. See the FRA:KN8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
71GF Score
Get the complete analysis for FRA:KN8
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KN8 has been successfully added to your 
